AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- Kroger cuts same-store sales outlook, keeps earnings guidance
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Abbvie (ABBV) PT Raised to $135 at RBC Capital
February 4, 2021 7:00 AM ESTRBC Capital analyst Randall Stanicky raised the price target on Abbvie (NYSE: ABBV) to $135.00 (from $129.00) while maintaining a Outperform rating. Overall, the outlook feels stable and very notably to Stanicky like a clear contrast to large cap biopharma peers dealing with mid-2020's... More
AbbVie (ABBV) Tops Q4 EPS by 6c, Offers FY Guidance
February 3, 2021 7:39 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $2.92, $0.06 better than the analyst estimate of $2.86. Revenue for the quarter came in at $13.86 billion versus the consensus estimate of $13.73 billion.
GUIDANCE:
AbbVie sees FY2021 EPS of $12.32-$12.52, versus the consensus of $12.18.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More